NCT03769467 - Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

August 19, 2021

Study Completion Date

August 19, 2021

Conditions

Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsEpstein-Barr Virus InfectionsEpstein-Barr ViraemiaEpstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Interventions

BIOLOGICAL

Tabelecleucel

Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

BIOLOGICAL

Pembrolizumab

pembrolizumab IV infusion

Trial Locations (7)

10016

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania (Adults and Pediatrics), Philadelphia

91010

City of Hope, Duarte

94305

Stanford Hospital and Clinics, Palo Alto

02114

Massachusetts General Hospital, Boston

07962

Atlantic Health System / Morristown Medical Center, Morristown